[HTML][HTML] Translating RNA sequencing into clinical diagnostics: opportunities and challenges

SA Byron, KR Van Keuren-Jensen… - Nature Reviews …, 2016 - nature.com
With the emergence of RNA sequencing (RNA-seq) technologies, RNA-based biomolecules
hold expanded promise for their diagnostic, prognostic and therapeutic applicability in …

Enabling personalized cancer medicine through analysis of gene-expression patterns

LJ Van't Veer, R Bernards - Nature, 2008 - nature.com
Therapies for patients with cancer have changed gradually over the past decade, moving
away from the administration of broadly acting cytotoxic drugs towards the use of more …

I‐SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

AD Barker, CC Sigman, GJ Kelloff… - Clinical …, 2009 - Wiley Online Library
I‐SPY 2 (investigation of serial studies to predict your therapeutic response with imaging
and molecular analysis 2) is a process targeting the rapid, focused clinical development of …

Breast cancer, screening and diagnostic tools: All you need to know

D Barba, A León-Sosa, P Lugo, D Suquillo… - Critical reviews in …, 2021 - Elsevier
Breast cancer is one of the most frequent malignancies among women worldwide. Methods
for screening and diagnosis allow health care professionals to provide personalized …

[HTML][HTML] Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges

SJ Mandrekar, DJ Sargent - Journal of Clinical Oncology, 2009 - ncbi.nlm.nih.gov
Purpose Biomarkers can add substantial value to current medical practice by providing an
integrated approach to prediction using the genetic makeup of the tumor and the genotype …

Clinical application of the 70-gene profile: the MINDACT trial

F Cardoso, L Van't Veer, E Rutgers, S Loi… - Journal of clinical …, 2008 - ascopubs.org
The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk
assessment and treatment decision making for early breast cancer. Its prospective validation …

Spatially resolved metabolic phenotyping of breast cancer by desorption electrospray ionization mass spectrometry

S Guenther, LJ Muirhead, AVM Speller, O Golf… - Cancer research, 2015 - AACR
Breast cancer is a heterogeneous disease characterized by varying responses to
therapeutic agents and significant differences in long-term survival. Thus, there remains an …

Molecular pathology of breast cancer: what a pathologist needs to know

KH Allison - American journal of clinical pathology, 2012 - academic.oup.com
Pathologists are now more than ever “diagnostic oncologists” and serve a critical role as
clinical consultants on the biology of disease. In the last decade and a half, molecular …

Cancer biomarker discovery: current status and future perspectives

K Mäbert, M Cojoc, C Peitzsch, I Kurth… - … journal of radiation …, 2014 - Taylor & Francis
Purpose: Cancer is a multigene disease which arises as a result of mutational and
epigenetic changes coupled with activation of complex signaling networks. The use of …

[HTML][HTML] Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

R Colomer, I Aranda-López, J Albanell… - Clinical and …, 2018 - Springer
This consensus statement revises and updates the recommendations for biomarkers use in
the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society …